94 related articles for article (PubMed ID: 20230608)
1. GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.
Jejcic A; Höglund S; Vahlne A
Retrovirology; 2010 Mar; 7():20. PubMed ID: 20230608
[TBL] [Abstract][Full Text] [Related]
2. Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion.
Youssefi M; Vahlne A
J Pharm Pharmacol; 2014 Oct; 66(10):1388-93. PubMed ID: 24780097
[TBL] [Abstract][Full Text] [Related]
3. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
4. Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation.
Jejcic A; Daniels R; Goobar-Larsson L; Hebert DN; Vahlne A
J Virol; 2009 Oct; 83(19):10075-84. PubMed ID: 19640982
[TBL] [Abstract][Full Text] [Related]
5. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
Balzarini J; Andersson E; Schols D; Proost P; Van Damme J; Svennerholm B; Horal P; Vahlne A
Int J Biochem Cell Biol; 2004 Sep; 36(9):1848-59. PubMed ID: 15183349
[TBL] [Abstract][Full Text] [Related]
6. Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.
Andersson E; Horal P; Jejcic A; Höglund S; Balzarini J; Vahlne A; Svennerholm B
Antimicrob Agents Chemother; 2005 Jan; 49(1):40-4. PubMed ID: 15616273
[TBL] [Abstract][Full Text] [Related]
7. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.
Su J; Andersson E; Horal P; Naghavi MH; Palm A; Wu YP; Eriksson K; Jansson M; Wigzell H; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):1-7. PubMed ID: 11213928
[TBL] [Abstract][Full Text] [Related]
8. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
Raja NU; Vincent MJ; Jabbar MA
J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
[TBL] [Abstract][Full Text] [Related]
9. ERManI (Endoplasmic Reticulum Class I α-Mannosidase) Is Required for HIV-1 Envelope Glycoprotein Degradation via Endoplasmic Reticulum-associated Protein Degradation Pathway.
Zhou T; Frabutt DA; Moremen KW; Zheng YH
J Biol Chem; 2015 Sep; 290(36):22184-92. PubMed ID: 26205822
[TBL] [Abstract][Full Text] [Related]
10. The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway.
Zhou T; Dang Y; Zheng YH
J Virol; 2014 Mar; 88(6):3474-84. PubMed ID: 24403586
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Vpr increases Env expression by preventing Env from endoplasmic reticulum-associated protein degradation (ERAD).
Zhang X; Zhou T; Frabutt DA; Zheng YH
Virology; 2016 Sep; 496():194-202. PubMed ID: 27343732
[TBL] [Abstract][Full Text] [Related]
12. Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.
Casini A; Olivieri M; Vecchi L; Burrone OR; Cereseto A
J Virol; 2015 Mar; 89(5):2966-71. PubMed ID: 25540359
[TBL] [Abstract][Full Text] [Related]
13. No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide.
Andersson E; Horal P; Vahlne A; Svennerholm B
Antiviral Res; 2004 Feb; 61(2):119-24. PubMed ID: 14670585
[TBL] [Abstract][Full Text] [Related]
14. Intracellular degradation of the HIV-1 envelope glycoprotein. Evidence for, and some characteristics of, an endoplasmic reticulum degradation pathway.
Courageot J; Fenouillet E; Bastiani P; Miquelis R
Eur J Biochem; 1999 Mar; 260(2):482-9. PubMed ID: 10095785
[TBL] [Abstract][Full Text] [Related]
15. Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.
Fenouillet E; Miquelis R; Drillien R
Virology; 1996 Apr; 218(1):224-31. PubMed ID: 8615025
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology.
Abdurahman S; Végvári A; Levi M; Höglund S; Högberg M; Tong W; Romero I; Balzarini J; Vahlne A
Retrovirology; 2009 Apr; 6():34. PubMed ID: 19356241
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
19. Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity.
Misra A; Gleeson E; Wang W; Ye C; Zhou P; Kimata JT
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321330
[TBL] [Abstract][Full Text] [Related]
20. Role of the HIV-1 envelope transmembrane domain in intracellular sorting.
Perrin J; Bary A; Vernay A; Cosson P
BMC Cell Biol; 2018 Mar; 19(1):3. PubMed ID: 29544440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
